Latest News about EBS
Recent news which mentions EBS
   The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
   
  
  
  February 20, 2022
  From Benzinga
 
   Johnson & Johnson's COVID-19 Shot Wins Its First Full Approval In Canada
   
  
  
  November 24, 2021
  From Benzinga
 
   The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
   
  
  
  November 12, 2021
  From Benzinga
 
   Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021
   
  
  
  November 08, 2021
  From Benzinga
 
   92 Biggest Movers From Friday
   
  
  
  November 08, 2021
  From Benzinga
 
   See Why Emergent BioSolutions Stock Plunged 37% On Friday?
   
  
  
  November 05, 2021
  From Benzinga
 
   Mid-Afternoon Market Update: Dow Surges 200 Points; Grid Dynamics Shares Spike Higher
   
  
  
  November 05, 2021
  From Benzinga
 
   12 Health Care Stocks Moving In Friday's Intraday Session
   
  
  
  November 05, 2021
  From Benzinga
 From Benzinga
 
   64 Stocks Moving In Friday's Mid-Day Session
   
  
  
  November 05, 2021
  From Benzinga
 
   Why Emergent Biosolutions Stock Is Crashing Today
   
  
  
  November 05, 2021
  From Motley Fool
 
   Pfizer’s positive antiviral news raises hopes for a new easy-to-take treatment for COVID-19, and cases start to rise again in California
   
  
  
  November 05, 2021
  From MarketWatch
 
   The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
   
  
  
  November 05, 2021
  From Benzinga
 
   A jog down memory lane shows the factor that mattered most to driving stocks — and it sure wasn’t interest rates
   
  
  
  November 05, 2021
  From MarketWatch
 
   Emergent BioSolutions inc (EBS) Q3 2021 Earnings Call Transcript
   
  November 05, 2021
  Tickers 
   EBS
  
  
  From Motley Fool
 
   12 Health Care Stocks Moving In Thursday's After-Market Session
   
  
  
  November 04, 2021
  From Benzinga
 
   The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
   
  
  
  November 04, 2021
  From Benzinga
 
   The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
   
  
  
  October 31, 2021
  From Benzinga
 From Motley Fool
 From Benzinga
 
   The Daily Biotech Pulse: Moderna's Booster Shot Gets FDA Panel Backing, Decision Day For Avadel, Silence Therapeutics Strikes Licensing Deal, MiNK IPO
   
  
  
  October 15, 2021
  From Benzinga
 
   5 Value Stocks To Watch In The Healthcare Sector
   
  
  
  October 11, 2021
  From Benzinga
 
   The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
   
  
  
  October 01, 2021
  From Benzinga
 
   The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
   
  
  
  September 30, 2021
  From Benzinga
 
   The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
   
  
  
  September 29, 2021
  From Benzinga
 
   The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
   
  
  
  September 28, 2021
  From Benzinga
 
   The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
   
  
  
  September 22, 2021
  From Benzinga
 
   Emergent Secures Contract To Manufacture Providence Therapeutics' COVID-19 Vaccine Candidate
   
  September 14, 2021
  Tickers 
   EBS
  
  
  From Benzinga
 
   8 F-Rated Stocks to Sell in September
   
  
  
  September 10, 2021
  From InvestorPlace
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.